NR3C2 and diabetes mellitus: Finerenone, a novel non-steroidal selective mineralocorticoid receptor antagonist, has garnered wider attention due to its benefits in chronic kidney disease and diabetes patients and its ability to reduce cardiovascular event risk in large studies (6, 10).